Bse Healthcare

Zydus Lifesciences has enclosed a copy of press release dated May 6, 2026, titled ‘USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad’. The contents of the press release give full details.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma’s Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana from January 28 to February 10, 2026. At the end of the inspection, a ‘Form 483’ was issued with a total of 9 observations. The Unit has now received Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is now closed.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the SEBI Listing Regulations and based on the recommendation of the Nomination and Remuneration Committee, Emcure Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held today i.e. Tuesday, May 05, 2026, has approved the re-appointment of the following Directors, subject to approval of shareholders: 1. Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company for a further period of 1 (One) year commencing from August 28, 2026; 2. Satish Mehta (DIN: 00118691) as the Managing Director of the Company, for a further period of 5 (Five) years with effective from April 01, 2027. Dr. Mukund Gurjar and Satish Mehta are not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India (‘SEBI’) SEBI order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and that they are not related to any Director(s) or Key Managerial Personnel(s) of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed. The meeting of the Board of Directors of the Company commenced at 12.42 pm (IST) and concluded at 2.00 pm (IST).

The above information is a part of company’s filings submitted to BSE.

Sanofi Consumer Healthcare India has informed that the Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon India Mutual Fund.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences has informed that it enclosed Receipt of Demand Order-In-Original from Deputy Commissioner of CGST & Central Excise, Ahmedabad North Commissionerate by Zydus VTEC, a wholly owned subsidiary company.

The above information is a part of company’s filings submitted to BSE.